Cargando…
Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis
Background Treating chronic hepatitis C (CHC) with direct-acting antiviral (DAA) is very effective at clearing the infection. In Albania treatment with DAA is limited to patients with liver stiffness F3-F4, and with other co-infections. The objective of this study was to evaluate the efficacy of DAA...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759809/ https://www.ncbi.nlm.nih.gov/pubmed/36540321 http://dx.doi.org/10.7759/cureus.32646 |
_version_ | 1784852315016003584 |
---|---|
author | Cuko, Liri Bele, Sonila Babameto, Adriana Tafaj, Irgen Hysenj, Arlinda Shagla, Eva Dogjani, Agron |
author_facet | Cuko, Liri Bele, Sonila Babameto, Adriana Tafaj, Irgen Hysenj, Arlinda Shagla, Eva Dogjani, Agron |
author_sort | Cuko, Liri |
collection | PubMed |
description | Background Treating chronic hepatitis C (CHC) with direct-acting antiviral (DAA) is very effective at clearing the infection. In Albania treatment with DAA is limited to patients with liver stiffness F3-F4, and with other co-infections. The objective of this study was to evaluate the efficacy of DAA in Albanian patients with genotypes 1-5, who mostly suffer from advanced liver fibrosis. Material and Methods This is a retrospective study carried out at the University Hospital Center “Mother Teresa”, Tirana, during 2014-2019, including treatment-naïve and treatment-experienced patients with genotypes 1-5. All patients were evaluated with elastography and most of them were F3-F4. The primary endpoint involved the patients achieving SVR-12, or undetectable hepatitis C virus/ribonucleic acid (HCV RNA) 12 weeks after the end of treatment. In patients without a genotype, we have used a pangenotypic regimen. Results This study included 207 patients with a mean age of 48.9 ± 13.1 years, 56% male and 44% female; 152 (73%) were genotype 1, 24 were (11.5%) genotype 2, nine were (4.3%) genotype 3, 14 were (6.7%) genotype 4, one was (0.4%) genotype 5, and seven (3.8%) unassigned genotypes. The sustained virologic response (SVR) percentage according to genotype is discussed in the article. The overall SVR score of all the patients in our study was >93%. According to elastography, 127 (66%) were F3-F4, and 80 (38.6%) were F1-F2. Conclusion Treatment with DAA proved to be very effective in our patients; most of them had advanced liver fibrosis as well as compensated or decompensated liver cirrhosis. The overall SVR score of the patients in our study was >93%. Our country needs to treat all patients with chronic hepatitis C without limitations to attain the WHO objective of eradicating this disease by 2030. |
format | Online Article Text |
id | pubmed-9759809 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-97598092022-12-19 Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis Cuko, Liri Bele, Sonila Babameto, Adriana Tafaj, Irgen Hysenj, Arlinda Shagla, Eva Dogjani, Agron Cureus Internal Medicine Background Treating chronic hepatitis C (CHC) with direct-acting antiviral (DAA) is very effective at clearing the infection. In Albania treatment with DAA is limited to patients with liver stiffness F3-F4, and with other co-infections. The objective of this study was to evaluate the efficacy of DAA in Albanian patients with genotypes 1-5, who mostly suffer from advanced liver fibrosis. Material and Methods This is a retrospective study carried out at the University Hospital Center “Mother Teresa”, Tirana, during 2014-2019, including treatment-naïve and treatment-experienced patients with genotypes 1-5. All patients were evaluated with elastography and most of them were F3-F4. The primary endpoint involved the patients achieving SVR-12, or undetectable hepatitis C virus/ribonucleic acid (HCV RNA) 12 weeks after the end of treatment. In patients without a genotype, we have used a pangenotypic regimen. Results This study included 207 patients with a mean age of 48.9 ± 13.1 years, 56% male and 44% female; 152 (73%) were genotype 1, 24 were (11.5%) genotype 2, nine were (4.3%) genotype 3, 14 were (6.7%) genotype 4, one was (0.4%) genotype 5, and seven (3.8%) unassigned genotypes. The sustained virologic response (SVR) percentage according to genotype is discussed in the article. The overall SVR score of all the patients in our study was >93%. According to elastography, 127 (66%) were F3-F4, and 80 (38.6%) were F1-F2. Conclusion Treatment with DAA proved to be very effective in our patients; most of them had advanced liver fibrosis as well as compensated or decompensated liver cirrhosis. The overall SVR score of the patients in our study was >93%. Our country needs to treat all patients with chronic hepatitis C without limitations to attain the WHO objective of eradicating this disease by 2030. Cureus 2022-12-17 /pmc/articles/PMC9759809/ /pubmed/36540321 http://dx.doi.org/10.7759/cureus.32646 Text en Copyright © 2022, Cuko et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Cuko, Liri Bele, Sonila Babameto, Adriana Tafaj, Irgen Hysenj, Arlinda Shagla, Eva Dogjani, Agron Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis |
title | Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis |
title_full | Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis |
title_fullStr | Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis |
title_full_unstemmed | Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis |
title_short | Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis |
title_sort | direct-acting antiviral treatment in albanian patients with chronic hepatitis c and advanced liver fibrosis |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759809/ https://www.ncbi.nlm.nih.gov/pubmed/36540321 http://dx.doi.org/10.7759/cureus.32646 |
work_keys_str_mv | AT cukoliri directactingantiviraltreatmentinalbanianpatientswithchronichepatitiscandadvancedliverfibrosis AT belesonila directactingantiviraltreatmentinalbanianpatientswithchronichepatitiscandadvancedliverfibrosis AT babametoadriana directactingantiviraltreatmentinalbanianpatientswithchronichepatitiscandadvancedliverfibrosis AT tafajirgen directactingantiviraltreatmentinalbanianpatientswithchronichepatitiscandadvancedliverfibrosis AT hysenjarlinda directactingantiviraltreatmentinalbanianpatientswithchronichepatitiscandadvancedliverfibrosis AT shaglaeva directactingantiviraltreatmentinalbanianpatientswithchronichepatitiscandadvancedliverfibrosis AT dogjaniagron directactingantiviraltreatmentinalbanianpatientswithchronichepatitiscandadvancedliverfibrosis |